Unique ID issued by UMIN | UMIN000014626 |
---|---|
Receipt number | R000017016 |
Scientific Title | DGS therapy for cervical esophageal carcinoma or cervical metastasis of esophageal carcinoma PI/II study |
Date of disclosure of the study information | 2014/07/23 |
Last modified on | 2017/01/23 12:03:00 |
DGS therapy for cervical esophageal carcinoma or cervical metastasis of esophageal carcinoma PI/II study
DGS therapy for esophageal cancer PI/II study
DGS therapy for cervical esophageal carcinoma or cervical metastasis of esophageal carcinoma PI/II study
DGS therapy for esophageal cancer PI/II study
Japan |
esophageal cancer
Gastrointestinal surgery |
Malignancy
NO
Phase I test
combination with docetaxel in TS-1 and nedaplatin. The nedaplatin 40mg/m2, TS-determine the maximum tolerated dose of docetaxel, the optimal dose is fixed to 80mg/m2.
PhaseII trial
the safety and efficacy were observed to 20 cases in the optimum dosage.
Safety,Efficacy
Study of efficacy and safety and the setting of optimal capacity
Interventional
Parallel
Non-randomized
Open -no one is blinded
Dose comparison
2
Prevention
Medicine |
DGS
DCF
20 | years-old | <= |
75 | years-old | > |
Male and Female
cervical esophageal carcinoma or cervical metastasis of esophageal carcinoma
Regardless of the adjuvant therapy, (tegafur, gimeracil, Oterashiru component of cases TS-capsule with a history of severe hypersensitivity to the 80-containing formulations polysorbate cases and docetaxel there is a treatment history TS-capsule, docetaxel, nedaplatin patients with a history of severe hypersensitivity to the formulation containing platinum or other cases nedaplatin with a history of severe hypersensitivity to the potassium)
Cases of disease-free period with active double cancer of less than 5 years
Cases (intestinal paralysis, intestinal obstruction, interstitial pneumonia, lung fibrosis, it is difficult to control diabetes, etc.) have a serious complication
Cases with active infection
Patients with edema requiring treatment
Pleural effusion requiring treatment, patients with ascites
Patients with a wide range of bone metastases
30
1st name | |
Middle name | |
Last name | Yoshihiro Tanaka |
Gifu University
Surgical Oncology
1-1 Yanagido Gifu City
0582306000
yoshihirotana11@hotmail.com
1st name | |
Middle name | |
Last name | Yoshihiro Tanaka |
Gifu University
Surgical Oncology
1-1 Yanagido Gifu City
0582306000
yoshihirotana11@hotmail.com
gifu university
self funding
Self funding
NO
2014 | Year | 07 | Month | 23 | Day |
Published
Completed
2009 | Year | 01 | Month | 07 | Day |
2009 | Year | 01 | Month | 07 | Day |
2014 | Year | 07 | Month | 23 | Day |
2017 | Year | 01 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017016
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |